Where Guidance and Caring Support Come Together

You’re ready to start growth hormone therapy, but understanding and securing insurance coverage can be complicated. However, with a little extra guidance and care, you may find your way through. At Humatrope DirectConnect, we’re here to help you every step of the way. From navigating insurance coverage to providing support throughout therapy, we’ll surround you with the caring support you need to see you through the process.

Humatrope DirectConnect | 1-84Humatrope (1-844-862-8767) | Insurance Assistance | HumatroPen® Training | Ongoing Support

SELECT SAFETY INFORMATION

Humatrope should not be used by:

  • People with serious complications after having open heart surgery, abdominal surgery, serious injuries involving many body systems, or with life-threatening breathing problems
  • Children with Prader-Willi syndrome who are severely obese or have a history of severe breathing problems
  • People with active cancer
  • People who have had an allergic reaction to growth hormone
  • People with diabetic disease of the retina (the lining in the back of the eyeball)
  • Children who have closed growth plates in their bones
Insurance Assistance
Once you are prescribed Humatrope, a Patient Service Liaison will be dedicated to providing guidance and caring support through Humatrope DirectConnect. Your Patient Service Liaison is an insurance specialist — specifically trained to understand the most effective and efficient ways to work with insurance companies — who will be your personal advocate to help you navigate through the insurance process.

SELECT SAFETY INFORMATION

  • Tell your doctor about all of your prescription and over the counter drugs, including cyclosporine, hormone replacement therapy, insulin or other diabetes medications, drugs containing steroids, or drugs for seizures. These medications may need to be adjusted while taking Humatrope.

Getting Started with Humatrope DirectConnect

If your doctor decides to work with Humatrope DirectConnect, here’s how we can start to work with you:

Talk to your doctor about starting to work with Humatrope DirectConnect. Talk to your doctor about starting to work with Humatrope DirectConnect.
Talk to your doctor about starting to work with Humatrope DirectConnect.
What concerns do you have?
  • Who will help me figure out the insurance process?
  • Who will help me learn how to use a HumatroPen?
  • Who will be there for me once treatment starts?
  • Select any question above to learn more.

Your Personal, Dedicated Insurance Advocate

Your Patient Service Liaison will contact your insurance company on your behalf, as well as collect and pass along all the information necessary to help your insurance company make their coverage decision.

In addition, your Patient Service Liaison will provide you with information about the Temporary Medication Program, which, should you qualify, can allow your doctor to start you or your child on Humatrope therapy while your insurance coverage is being evaluated.

When deciding whether to begin Humatrope therapy before insurance coverage is in place, please keep in mind the possibility of therapy being discontinued if coverage is denied by your insurer. Also consider that the amount of therapy you may receive before a coverage decision is reached will be limited.

If eligible for appeals support of prior authorization denials, your Patient Service Liaison will also be your main point of contact. Your Patient Service Liaison will work with your Appeals Specialist and provide patients, caregivers, and doctors with follow-up and status updates throughout the appeals process. Please see Appeals Support above for more Appeals Support details and eligibility information.

Patient Authorization

Patient Authorization icon

To begin working with you, Humatrope DirectConnect must receive your permission (known as patient authorization) to investigate Humatrope treatment coverage on your behalf. Patient authorization can be given by faxing a completed Patient Authorization form to Humatrope DirectConnect or by giving authorization during the introductory phone call from Humatrope DirectConnect.

Please select an option below to review the Patient Authorization form, print a copy to fax, or send a copy to yourself by e-mail.

  • View the form
  • Print the form
  • E-mail the form

Receive a Patient Authorization Form by E-mail

Enter your e-mail address

*Please enter a valid e-mail address.

  • Send me a form
  • Cancel

Thank You

The Patient Authorization form you requested has been sent to [Patient’s Email Address] in an e-mail from Lilly.

Messaging Error

The Patient Authorization form was not able to be mailed at this time. The error was .

Key Steps in Insurance Investigation

Preparing for Approval

Talk with your doctor

Ask your doctor if Humatrope therapy can start before insurance coverage is in place. If you or your child has already started Humatrope therapy and your insurance plan changes, you may need a short-term arrangement to continue therapy until a decision about your new coverage has been reached. Humatrope DirectConnect offers qualifying patients a program that allows them to start or maintain Humatrope therapy for a limited time during the process of determining insurance coverage or identifying a new insurer.

Keep in mind

When deciding whether to start Humatrope therapy before insurance coverage is in place, keep in mind the possibility of therapy being discontinued if coverage is denied by your insurer. Also consider that the amount of therapy you may receive before a coverage decision is reached will be limited. We will be happy to provide you with more information if you would like to learn more.

Pursuing Approval

You’ll get a phone call from your Patient Service Liaison when it's time to begin the process. Your Patient Service Liaison will contact your insurance company on your behalf. Your Patient Service Liaison will collect and pass along all the necessary information your insurer requires to reach a decision, which can include information from your or your child's medical records.

With a number of steps in pursuing approval, it is important to note that this process can take from several days to several months to complete. But that doesn't necessarily mean you have to delay Humatrope treatment. See the Preparing for Approval section above to learn more.

If prior authorization is denied and you are eligible to receive Appeals Support from Humatrope DirectConnect, we will work with you and your doctor throughout the appeals process. Please see Appeals Support above for more Appeals Support details and eligibility information.

Securing Approval

If your insurance covers Humatrope therapy, your Patient Service Liaison will notify your preferred or in-network pharmacy. Your Patient Service Liaison will transfer your or your child's prescription and other medical information required by your pharmacy so they can contact you to arrange shipping of Humatrope.

Receiving Your Medication

HumatroPen® training — at no cost, at your convenience

Once you have received Humatrope from your pharmacy, call Humatrope DirectConnect to find a time for your personal HumatroPen training appointment. We’ll connect you with a Nurse Educator who specializes in training and helping people learn how to administer injections at home. Your physician may wish to conduct the training in his or her office, but you can also receive free HumatroPen training at a time and location that’s more convenient for you.

At Humatrope DirectConnect, we’ll talk with you to understand your needs as we schedule your HumatroPen® training session. We’ll do what we can to make training more convenient for you including training for more than one family member or caregiver, if necessary.

*In-home training subject to state regulations and availability of trained Nurse Educators.

Understanding Options

If your insurance company does not cover Humatrope therapy, your Patient Service Liaison will help you work with them to request coverage. Humatrope DirectConnect has helped many patients and caregivers in this way. If your insurance company continues to deny coverage, we will present information to you about other options.

Indications and Important Safety Information for Humatrope
Humatrope® (somatropin for injection) is used to treat:
  • Children who do not make enough growth hormone on their own, have short stature associated with Turner syndrome, or have SHOX deficiency; have idiopathic short stature, which means they are shorter than 98.8% of other children of the same age and sex, are growing at a rate not likely to allow them to reach normal adult height, and for whom no other cause of short stature can be found; were born smaller than normal for the number of weeks of pregnancy and who do not catch up in height by 2 to 4 years of age
  • Adults who have growth hormone deficiency that began either in adulthood (as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma) or in childhood. Patients treated for growth hormone deficiency in childhood whose bones have stopped growing should be reevaluated to determine if they should continue growth hormone
Important Safety Information for Humatrope
What is the most important information I should know about Humatrope?
  • Do not take Humatrope if you are having serious complications after having open heart surgery, abdominal surgery, or serious injuries involving many body systems, or are having life-threatening breathing problems. Deaths have been reported in such cases.
  • Do not use Humatrope in children with Prader-Willi syndrome who are severely obese or have a history of blocked upper airways or other severe breathing problems, or sleep apnea. Deaths have been reported in such cases. Humatrope is not approved for the treatment of patients with Prader-Willi syndrome.
  • Do not use Humatrope if you have active cancer. Growth hormone deficiency can be an early sign of some tumors in the brain or pituitary gland. The presence of these types of tumors should be ruled out by your doctor before you start Humatrope.
  • Serious allergic reactions have been reported with Humatrope. Humatrope is contraindicated if you know you have allergies to growth hormone or any of its ingredients. Tell your doctor if you have an allergic reaction. Do not mix Humatrope with the supplied diluent if you are allergic to metacresol or glycerin.
  • Your doctor should check your blood sugar regularly while you are taking Humatrope, especially if you have diabetes, pre-diabetes, or risk factors for diabetes. New cases of type 2 diabetes have been reported in patients taking Humatrope.
  • Tell your doctor if you have any visual changes accompanied by headache, nausea, and/or vomiting while taking Humatrope. This may be a sign of increased pressure in the brain.
  • Adults may retain water during Humatrope treatment. This may be brief and may increase with higher doses of Humatrope.
  • If you have hypoadrenalism and are on glucocorticoid replacement therapy, your doctor may increase your dosage when you initiate growth hormone treatment.
  • Your doctor should test your thyroid function periodically during Humatrope therapy. Thyroid hormone treatment may need to be started or adjusted.
  • Fracture in the ball of the hip joint can occur in children who have endocrine problems and in children who have rapid growth. Any child taking Humatrope who develops a limp or complains of hip or knee pain should be seen by a doctor to check for this.
  • Progression of curvature of the spine (scoliosis) can occur in children who have rapid growth. Humatrope has not been shown to increase the occurrence of this condition. If the child has scoliosis, the doctor should carefully monitor the progression of the scoliosis during Humatrope treatment.
  • Cases of pancreatitis (inflammation of the pancreas) have been reported rarely in children and adults receiving growth hormone. Consult a doctor if you develop abdominal pain while taking Humatrope.
  • You should rotate your injection sites to avoid breakdown of skin and fat. Seek prompt medical attention for any allergic reaction you experience to the injection of Humatrope.
Who should not take Humatrope?

Humatrope should not be used by:

  • People with serious complications after having open heart surgery, abdominal surgery, serious injuries involving many body systems, or with life-threatening breathing problems
  • Children with Prader-Willi syndrome who are severely obese or have a history of severe breathing problems
  • People with active cancer
  • People who have had an allergic reaction to growth hormone
  • People with diabetic disease of the retina (the lining in the back of the eyeball)
  • Children who have closed growth plates in their bones
What should I tell my doctor before taking Humatrope?

Tell your doctor about all of your prescription and over the counter drugs, including cyclosporine, hormone replacement therapy, insulin or other diabetes medications, drugs containing steroids, or drugs for seizures. These medications may need to be adjusted while taking Humatrope.

What are the possible side effects of Humatrope?

Common side effects reported in adults and children taking Humatrope include injection site reactions, allergic reactions to the diluent, and hypothyroidism. Additional common side effects in adults include swelling, joint pain, muscle pain, carpal tunnel syndrome, unusual skin sensations, and high blood sugar.

You are encouraged to report negative side effects of prescription drugs to the Food and Drug Administration (FDA). Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

How should I store Humatrope?

Humatrope must be kept refrigerated (36° to 46°F [2° to 8°C]) before and after it is mixed. Do not freeze. Once Humatrope has been mixed and is in liquid form, cartridges must be used within 28 days and vials must be used within 14 days. Throw away any unused Humatrope in a cartridge after 28 days and in a vial after 14 days. Before giving an injection, check the manufacturer’s expiration date on the cartridge or vial. Do not use the cartridge or vial if it has expired.

Humatrope is available by prescription only.
See Full Pen User Manual that accompanies the HumatroPen® 6 mg, 12 mg, and 24 mg.
HG CON ISI 14OCT2016